Naftifine cream 1% versus clotrimazole cream 1% in the treatment of tinea pedis. Naftifine Podiatric Study Group.
Fifty-seven subjects with tinea pedis applied naftifine cream 1% or clotrimazole cream 1% to affected areas twice daily for 4 to 6 weeks in a double-blind, randomized trial. Throughout the study, more naftifine-treated than clotrimazole-treated subjects were mycologically cured and globally improved, although differences were not statistically significant. Similar trends favoring naftifine were observed in the resolution of signs and symptoms. Treatment differences noted as early as week 2 suggest that naftifine may have a more rapid onset of action than clotrimazole.
D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000499:Allylamine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000588:Amines / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003022:Clotrimazole / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D014008:Tinea Pedis / Q000188:drug therapy*
D000588:Amines; D000935:Antifungal Agents; D007093:Imidazoles; D000499:Allylamine; C029178:naftifine; D003022:Clotrimazole